• In chicken ovary the adiponectin gene was found to

  2023-06-02

  

  In chicken ovary, the adiponectin gene was found to be mainly expressed in theca cells and is suggested to exert a paracrine or autocrine effect on ovarian steroidogenesis (Chabrolle et al., 2007). A limited number of studies have revealed the effect of adiponectin on ovarian steroidogenesis or its

• Application of the broad acting HTR antagonist

  2023-06-01

  

  Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L

• Regorafenib receptor Control of retinal vascularization duri

  2023-06-01

  

  Control of retinal vascularization during development and OIR likely involves close interactions among endothelial cells, neurons and glial Regorafenib receptor (microglial and astrocytes) (see Fig. 2). In particular, the interaction between endothelial tip cells and astrocytes plays a critical role

• During the year study period of men in the dutasteride

  2023-05-30

  

  During the 4-year study period, 19.9% of men in the dutasteride group developed prostate cancer as compared to 25.1% in the placebo group, which represents an absolute risk Famprofazone of 5.1% for men taking dutasteride (Pe weighed against the prospect of undesirable sexual side effects and decrea

• br Conclusion br List of abbreviations br

  2023-05-30

  

  Conclusion List of abbreviations Acknowledgment The studies performed by our laboratory and presented in this review were supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan, (KAKENHI 17590618 [to H.I.] and KAKENHI 22249017 [to Y.Y.]), and the Japanese

• Pompe disease is accompanied by the deficiency of

  2023-05-30

  

  Pompe disease is accompanied by the deficiency of the lysosomal α-1,4-glucosidase that makes the SB 242084 unable to hydrolyze glycogen to glucose, thereby resulting in the accumulation of glycogen in lysosomes, especially in skeletal muscles and cardiac tissues. This accumulation results in the str

• Consistent with a damaging role

  2023-05-30

  

  Consistent with a damaging role for increased 12/15-LOX activity in stroke, systemic administration of the 12/15-LOX inhibitor, LB1, 2 h after permanent focal cerebral ischemia significantly reduced infarct size 24 h after the ischemia, and the treatment group demonstrated improved behavioral and he

• Finally we argue that the

  2023-05-29

  

  Finally, we argue that the estimated penetrance of 0.45% (95% CI 0.02%, 9.35%) calculated by leveraging the gnomAD (Lek et al., 2016) population data indicate that T201S is at most a low-risk gene variant for CJD. If we arbitrarily consider a central estimate of 10% or higher as the clinically signi

• A phase I trial has recently evaluated

  2023-05-29

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• br Introduction AMP activated protein kinase AMPK

  2023-05-29

  

  Introduction AMP-activated protein kinase (AMPK) has been found to be a key character against cardiovascular diseases and cellular stress. When activated by certain stress, AMPK regulates sugars and fatty acids that are good or detrimental to the heart. For example, targeting AMPK phosphorylation

• Following activation of mGluRs GRIP stabilized AMPARs appear

  2023-05-29

  

  Following activation of mGluRs, GRIP-stabilized AMPARs appear to be the primary target for endocytosis. Consistent with this model, we find that using siRNA to reduce GRIP1/2 expression blocks the AMPAR internalization and the synaptic depression mediated by mGluRs. Reductions in GRIP1/2 expression,

• br Conclus o br Conflitos

  2023-05-29

  

  Conclusão Conflitos de interesses Alzheimer Disease: Common and Complex Alzheimer’s disease (AD) is a genetically complex, multifactorial disease that leads to neurodegenerative dementia. There is no cure for AD yet, and due to a high prevalence and continuously increasing incidence it pose

• br Development of lorlatinib from

  2023-05-29

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• ALK fusion positive NSCLC is clinically

  2023-05-29

  

  ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective

• br Conclusions br Introduction During numerous

  2023-05-29

  

  Conclusions Introduction During numerous physiological processes, aldehydes are generated from a variety of endogenous and exogenous precursors including amino acids, carbohydrates, and lipids [1]. Most aldehydes are highly reactive and cytotoxic due to the strong electrophilic nature of the t

15923 records 332/1062 page Previous Next First page 上5页 331332333334335 下5页 Last page